Vizsgálati helyszín
Ege University Medical Faculty
Izmir, 35100, TörökországMég nincs intézményhez kötve
- 14futó vizsgálat
- 17lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 31 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis22 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Fut, nem toboroz10 vizsgálat
- Leállították4 vizsgálat
- Toboroz3 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Hoffmann-La Roche6 vizsgálat
- Janssen Research & Development, LLC6 vizsgálat
- Pfizer3 vizsgálat
- Takeda2 vizsgálat
- Abivax S.A.1 vizsgálat
- és még 13
Futó vizsgálatok
Toboroz
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· 3. fázis· Takeda· Forrás
Contact: Guray Saydam (principal investigator)
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· 1/2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095· 3. fázis· Janssen-Cilag Ltd.· Forrás
Fut, nem toboroz
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
NCT04370054· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
NCT03459534· 3. fázis· Il-Yang Pharm. Co., Ltd.· Forrás
Contact: Na Yun Kim
Fut, nem toboroz
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608· 3. fázis· Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Cough Reduction in IPF With Nalbuphine ER
NCT05964335· 2. fázis· Trevi Therapeutics· Forrás
Leállították
A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)
NCT05580692· BioMarin Pharmaceutical· Forrás
Lezárult
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203· 3. fázis· Abivax S.A.· Forrás
Lezárult
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
NCT05275023· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Olorofim Aspergillus Infection Study
NCT05101187· 3. fázis· F2G Ltd· Forrás
Leállították
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
NCT05305040· 2/3. fázis· AlloVir· Forrás
Leállították
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
NCT04963270· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· 3. fázis· Hoffmann-La Roche· Forrás
Leállították
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
NCT04271475· 3. fázis· Actelion· Forrás
Lezárult
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
NCT03938792· 3. fázis· Pfizer· Forrás
Lezárult
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
NCT03969212· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
NCT03593590· Hoffmann-La Roche· Forrás
Lezárult
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03358875· 3. fázis· BeiGene· Forrás
Lezárult
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954· 3. fázis· Takeda· Forrás
Lezárult
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
NCT03194893· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Avelumab in First-line NSCLC (JAVELIN Lung 100)
NCT02576574· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Hibát jelzek